NASDAQ:RETA - Reata Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$32.02 +0.17 (+0.53 %)
(As of 05/23/2018 01:33 AM ET)
Previous Close$32.02
Today's Range$31.62 - $32.64
52-Week Range$19.31 - $40.88
Volume146,245 shs
Average Volume203,650 shs
Market Capitalization$825.47 million
P/E Ratio-16.09
Dividend YieldN/A
Beta0.1

About Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals logoReata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease. It is also developing omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.

Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219

Debt

Debt-to-Equity Ratio-0.12
Current Ratio2.62
Quick Ratio2.62

Price-To-Earnings

Trailing P/E Ratio-16.09
Forward P/E Ratio-14.96
P/E GrowthN/A

Sales & Book Value

Annual Sales$48.06 million
Price / Sales17.43
Cash FlowN/A
Price / CashN/A
Book Value($5.62) per share
Price / Book-5.70

Profitability

EPS (Most Recent Fiscal Year)($1.99)
Net Income$-47,670,000.00
Net Margins-53.89%
Return on EquityN/A
Return on Assets-28.97%

Miscellaneous

Employees93
Outstanding Shares26,160,000

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals (NASDAQ:RETA) posted its quarterly earnings results on Tuesday, May, 8th. The company reported $0.15 EPS for the quarter, topping the Zacks' consensus estimate of ($0.61) by $0.76. The company earned $32.39 million during the quarter, compared to the consensus estimate of $10.21 million. View Reata Pharmaceuticals' Earnings History.

What price target have analysts set for RETA?

8 equities research analysts have issued 1-year price targets for Reata Pharmaceuticals' stock. Their forecasts range from $43.00 to $78.00. On average, they expect Reata Pharmaceuticals' stock price to reach $54.7143 in the next year. View Analyst Ratings for Reata Pharmaceuticals.

What are Wall Street analysts saying about Reata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (5/9/2018)
  • 2. Cowen Inc analysts commented, "RETA reported 3Q17 financials yesterday, noting that the three major programs." (11/14/2017)

Who are some of Reata Pharmaceuticals' key competitors?

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the folowing people:
  • Mr. J. Warren Huff, Chairman, CEO & Pres (Age 64)
  • Dr. Colin J. Meyer, Chief Medical Officer & VP of Product Devel. (Age 39)
  • Dr. Keith W. Ward, VP & Chief Devel. Officer (Age 48)
  • Mr. Jason D. Wilson, CFO & VP of Strategy (Age 48)
  • Ms. Elaine Castellanos, VP of Fin. & Accounting and Principal Accounting Officer

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

Has Reata Pharmaceuticals been receiving favorable news coverage?

Media headlines about RETA stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Reata Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the company an impact score of 45.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.56%), Prosight Management LP (1.14%), JPMorgan Chase & Co. (0.65%), Northern Trust Corp (0.50%), King Luther Capital Management Corp (0.24%) and Landscape Capital Management L.L.C. (0.21%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, James Warren Huff and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wells Fargo & Company MN and BlackRock Inc.. View Insider Buying and Selling for Reata Pharmaceuticals.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Landscape Capital Management L.L.C., Sofinnova Ventures Inc, Citadel Advisors LLC, Stifel Financial Corp, UBS Group AG, DekaBank Deutsche Girozentrale and King Luther Capital Management Corp. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include A/S Novo, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, James Warren Huff and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $32.02.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $825.47 million and generates $48.06 million in revenue each year. The company earns $-47,670,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Reata Pharmaceuticals employs 93 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]


MarketBeat Community Rating for Reata Pharmaceuticals (RETA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Reata Pharmaceuticals (NASDAQ:RETA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Reata Pharmaceuticals in the last 12 months. Their average twelve-month price target is $54.7143, suggesting that the stock has a possible upside of 70.88%. The high price target for RETA is $78.00 and the low price target for RETA is $43.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.883.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.7143$54.7143$54.7143$54.7143
Price Target Upside: 70.88% upside174.39% upside116.95% upside117.21% upside

Reata Pharmaceuticals (NASDAQ:RETA) Consensus Price Target History

Price Target History for Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals (NASDAQ:RETA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018CowenReiterated RatingHoldHighView Rating Details
10/24/2017Robert W. BairdReiterated RatingBuy$47.00N/AView Rating Details
10/6/2017Jefferies GroupReiterated RatingBuy$44.00N/AView Rating Details
9/13/2017Leerink SwannInitiated CoverageOutperform ➝ Outperform$43.00MediumView Rating Details
8/23/2017CitigroupReiterated RatingBuy$87.00 ➝ $78.00HighView Rating Details
7/26/2017Ladenburg ThalmannReiterated RatingBuy$55.00 ➝ $61.00HighView Rating Details
7/25/2017Stifel NicolausReiterated RatingBuy$38.00 ➝ $50.00HighView Rating Details
7/24/2017Piper Jaffray CompaniesBoost Price TargetBuy$53.00 ➝ $60.00HighView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Reata Pharmaceuticals (NASDAQ:RETA) Earnings History and Estimates Chart

Earnings by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals (NASDAQ:RETA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.55)($0.55)($0.55)
Q2 20182($0.85)($0.63)($0.74)
Q3 20182($0.85)($0.66)($0.76)
Q4 20182($0.97)($0.69)($0.83)

Reata Pharmaceuticals (NASDAQ RETA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.6080)$0.1530$10.21 million$32.39 millionViewN/AView Earnings Details
3/2/2018Q4 2017($0.5630)($0.64)$11.18 million$9.96 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.3890)($0.4950)$12.54 million$12.60 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.32)($0.52)$12.58 million$12.81 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.11)($0.32)$12.48 million$12.73 millionViewN/AView Earnings Details
3/3/2017Q4 2016($0.13)($0.19)$12.49 million$12.50 millionViewN/AView Earnings Details
11/14/2016Q316($0.14)($0.04)$12.46 million$12.55 millionViewN/AView Earnings Details
8/11/2016Q216($0.08)($0.05)$12.40 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Reata Pharmaceuticals (NASDAQ:RETA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Reata Pharmaceuticals (NASDAQ RETA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.00%
Institutional Ownership Percentage: 50.33%
Insider Trading History for Reata Pharmaceuticals (NASDAQ:RETA)
Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals (NASDAQ RETA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2017James W Traweek JrMajor ShareholderBuy17,000$28.47$483,990.0035View SEC Filing  
12/29/2017R Kent Mcgaughy JrDirectorBuy17,000$28.47$483,990.00113View SEC Filing  
12/28/2017James W Traweek JrMajor ShareholderBuy27,200$25.93$705,296.0035View SEC Filing  
12/27/2017R Kent Mcgaughy JrDirectorBuy15,000$25.83$387,450.0025,004View SEC Filing  
12/26/2017James W Traweek JrMajor ShareholderBuy12,000$26.06$312,720.0035View SEC Filing  
12/14/2017Cpmg IncDirectorBuy200,000$24.79$4,958,000.00113View SEC Filing  
12/13/2017James W Traweek JrMajor ShareholderBuy121,725$24.88$3,028,518.0035View SEC Filing  
11/15/2017James Edward BassDirectorBuy3,888$24.02$93,389.7652,089View SEC Filing  
8/1/2017James Edward BassDirectorBuy8,064$31.00$249,984.0067,411View SEC Filing  
6/14/2017A/S NovoMajor ShareholderSell61,000$25.11$1,531,710.00642,405View SEC Filing  
6/13/2017A/S NovoMajor ShareholderSell11,389$25.47$290,077.83642,405View SEC Filing  
6/12/2017A/S NovoMajor ShareholderSell222,503$25.71$5,720,552.13746,297View SEC Filing  
6/7/2017A/S NovoMajor ShareholderSell89,497$28.24$2,527,395.28942,467View SEC Filing  
6/6/2017A/S NovoMajor ShareholderSell64,170$28.09$1,802,535.30942,467View SEC Filing  
6/5/2017A/S NovoMajor ShareholderSell23,327$28.67$668,785.09942,467View SEC Filing  
3/28/2017Abbvie Inc.Major ShareholderSell450,000$22.50$10,125,000.001,190,473View SEC Filing  
12/30/2016Cpmg IncDirectorBuy9,392$21.72$203,994.24113View SEC Filing  
12/16/2016Cpmg IncDirectorBuy164,753$22.99$3,787,671.47113View SEC Filing  
12/15/2016James W Traweek JrMajor ShareholderBuy8,889$21.57$191,735.7335View SEC Filing  
12/14/2016James Edward BassDirectorBuy5,000$21.76$108,800.0030,585View SEC Filing  
8/22/2016Jack NielsenDirectorBuy1,780$17.00$30,260.001,780View SEC Filing  
8/18/2016R Kent Mcgaughy JrDirectorBuy308,220$17.08$5,264,397.6025,004View SEC Filing  
8/16/2016Colin John MeyerInsiderBuy7,000$16.26$113,820.0027,172View SEC Filing  
6/30/2016James W Traweek JrMajor ShareholderBuy164,600$19.78$3,255,788.0035View SEC Filing  
6/27/2016Cpmg IncDirectorBuy73,403$19.26$1,413,741.78113View SEC Filing  
6/7/2016R Kent Mcgaughy JrDirectorBuy24,220$17.57$425,545.4025,004View SEC Filing  
6/1/2016A/S NovoMajor ShareholderBuy750,000$11.00$8,250,000.00750,000View SEC Filing  
6/1/2016James Warren HuffInsiderBuy114,000$11.00$1,254,000.0062,657View SEC Filing  
6/1/2016R Kent Mcgaughy JrDirectorBuy251,553$12.70$3,194,723.1025,004View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Reata Pharmaceuticals (NASDAQ RETA) News Headlines

Source:
DateHeadline
Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals ...Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals ...
globenewswire.com - May 18 at 11:21 AM
Reata Pharmaceuticals (RETA) CEO Warren Huff on Q1 2018 Results - Earnings Call TranscriptReata Pharmaceuticals' (RETA) CEO Warren Huff on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 10:33 AM
$9.52 Million in Sales Expected for Reata Pharmaceuticals (RETA) This Quarter$9.52 Million in Sales Expected for Reata Pharmaceuticals (RETA) This Quarter
www.americanbankingnews.com - May 13 at 2:34 AM
-$0.73 EPS Expected for Reata Pharmaceuticals (RETA) This Quarter-$0.73 EPS Expected for Reata Pharmaceuticals (RETA) This Quarter
www.americanbankingnews.com - May 11 at 7:31 PM
Q2 2018 EPS Estimates for Reata Pharmaceuticals (RETA) Reduced by AnalystQ2 2018 EPS Estimates for Reata Pharmaceuticals (RETA) Reduced by Analyst
www.americanbankingnews.com - May 11 at 9:34 AM
Reata Pharmaceuticals (RETA) Announces  Earnings Results, Beats Estimates By $0.76 EPSReata Pharmaceuticals (RETA) Announces Earnings Results, Beats Estimates By $0.76 EPS
www.americanbankingnews.com - May 10 at 5:11 PM
Edited Transcript of RETA earnings conference call or presentation 9-May-18 12:00pm GMTEdited Transcript of RETA earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 10:20 AM
Reata Pharmaceuticals (RETA) Raised to "Hold" at Zacks Investment ResearchReata Pharmaceuticals (RETA) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:11 PM
Reata Pharmaceuticals beats by $0.79, beats on revenueReata Pharmaceuticals beats by $0.79, beats on revenue
seekingalpha.com - May 9 at 10:08 AM
Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development ProgramsReata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs
finance.yahoo.com - May 9 at 10:08 AM
Reata Pharmaceuticals (RETA) Upgraded by BidaskClub to BuyReata Pharmaceuticals (RETA) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - May 9 at 8:52 AM
Reata Pharmaceuticals (RETA) Rating Lowered to Sell at Zacks Investment ResearchReata Pharmaceuticals (RETA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 3 at 9:52 PM
Reata Pharmaceuticals (RETA) Receives Consensus Rating of "Buy" from AnalystsReata Pharmaceuticals (RETA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 3 at 3:24 AM
Reata Pharmaceuticals (RETA) Stock Rating Upgraded by ValuEngineReata Pharmaceuticals (RETA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 6:30 PM
BidaskClub Upgrades Reata Pharmaceuticals (RETA) to "Hold"BidaskClub Upgrades Reata Pharmaceuticals (RETA) to "Hold"
www.americanbankingnews.com - May 2 at 1:10 PM
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreichs ...Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich's ...
globenewswire.com - April 26 at 10:04 AM
BRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of OmaveloxoloneBRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of Omaveloxolone
www.reuters.com - April 26 at 10:04 AM
$10.21 Million in Sales Expected for Reata Pharmaceuticals (RETA) This Quarter$10.21 Million in Sales Expected for Reata Pharmaceuticals (RETA) This Quarter
www.americanbankingnews.com - April 26 at 4:32 AM
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological DiseasesReata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases
finance.yahoo.com - April 25 at 10:39 AM
-$0.66 Earnings Per Share Expected for Reata Pharmaceuticals (RETA) This Quarter-$0.66 Earnings Per Share Expected for Reata Pharmaceuticals (RETA) This Quarter
www.americanbankingnews.com - April 24 at 8:08 AM
Reata Pharmaceuticals (RETA) Upgraded to "Sell" by BidaskClubReata Pharmaceuticals (RETA) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 20 at 11:55 AM
Citigroup Reaffirms "Buy" Rating for Reata Pharmaceuticals (RETA)Citigroup Reaffirms "Buy" Rating for Reata Pharmaceuticals (RETA)
www.americanbankingnews.com - April 16 at 1:54 PM
Reata Pharmas bardoxolone shows treatment effect in mid-stage portion of Alport syndrome studyReata Pharma's bardoxolone shows treatment effect in mid-stage portion of Alport syndrome study
seekingalpha.com - April 12 at 11:08 AM
Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport SyndromeReata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
finance.yahoo.com - April 12 at 11:08 AM
8 Stocks Moving In Wednesdays After-Hours Session8 Stocks Moving In Wednesday's After-Hours Session
feeds.benzinga.com - April 11 at 7:10 PM
Achillion, Omeros, Ra Rx, Reata, ChemoCentryx, And Others In The IgA Nephropathy SpaceAchillion, Omeros, Ra Rx, Reata, ChemoCentryx, And Others In The IgA Nephropathy Space
seekingalpha.com - April 9 at 3:56 PM
Cowen Reiterates "Hold" Rating for Reata Pharmaceuticals (RETA)Cowen Reiterates "Hold" Rating for Reata Pharmaceuticals (RETA)
www.americanbankingnews.com - April 9 at 6:02 AM
Zacks: Analysts Expect Reata Pharmaceuticals Inc (RETA) Will Post Quarterly Sales of $10.21 MillionZacks: Analysts Expect Reata Pharmaceuticals Inc (RETA) Will Post Quarterly Sales of $10.21 Million
www.americanbankingnews.com - April 9 at 3:32 AM
Reata Pharmaceuticals (RETA) Upgraded by ValuEngine to HoldReata Pharmaceuticals (RETA) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 8 at 7:34 PM
Reata Pharmaceuticals Inc (RETA) Given Average Rating of "Hold" by BrokeragesReata Pharmaceuticals Inc (RETA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 8 at 3:36 AM
Reata Pharmaceuticals (RETA) Downgraded by ValuEngineReata Pharmaceuticals (RETA) Downgraded by ValuEngine
www.americanbankingnews.com - April 7 at 8:50 PM
-$0.66 EPS Expected for Reata Pharmaceuticals Inc (RETA) This Quarter-$0.66 EPS Expected for Reata Pharmaceuticals Inc (RETA) This Quarter
www.americanbankingnews.com - April 7 at 9:53 AM
Reata Pharmaceuticals (RETA) Rating Increased to Hold at Zacks Investment ResearchReata Pharmaceuticals (RETA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:20 PM
Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology ConferenceReata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference
finance.yahoo.com - April 3 at 10:32 AM
Reata Pharmaceuticals (RETA) Stock Rating Lowered by ValuEngineReata Pharmaceuticals (RETA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 1 at 12:08 AM
Reata licensee Kyowa Hakko Kirin nabs accelerated review status in Japan for bardoxolone in DKDReata licensee Kyowa Hakko Kirin nabs accelerated review status in Japan for bardoxolone in DKD
seekingalpha.com - March 30 at 10:20 AM
Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in JapanReata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
finance.yahoo.com - March 30 at 10:20 AM
Zacks Investment Research Downgrades Reata Pharmaceuticals (RETA) to SellZacks Investment Research Downgrades Reata Pharmaceuticals (RETA) to Sell
www.americanbankingnews.com - March 26 at 10:58 AM
Reata Pharmaceuticals (RETA) Downgraded by BidaskClubReata Pharmaceuticals (RETA) Downgraded by BidaskClub
www.americanbankingnews.com - March 26 at 9:55 AM
U.S. Biotech/Pharma Sector Daily Observations Letter: March 22, 2018U.S. Biotech/Pharma Sector Daily Observations Letter: March 22, 2018
seekingalpha.com - March 24 at 4:23 PM
Reata Pharmaceuticals Inc (RETA) Expected to Announce Quarterly Sales of $10.21 MillionReata Pharmaceuticals Inc (RETA) Expected to Announce Quarterly Sales of $10.21 Million
www.americanbankingnews.com - March 23 at 4:56 AM
Reata Pharma (RETA) Reports Positive Top-Line Data for Treatment of PH-ILD with Bardoxolone Methyl From the ... - StreetInsider.comReata Pharma (RETA) Reports Positive Top-Line Data for Treatment of PH-ILD with Bardoxolone Methyl From the ... - StreetInsider.com
www.streetinsider.com - March 22 at 10:00 AM
Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat TrialReata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
finance.yahoo.com - March 22 at 10:00 AM
Reata Pharmaceuticals Inc (RETA) Expected to Announce Earnings of -$0.66 Per ShareReata Pharmaceuticals Inc (RETA) Expected to Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - March 21 at 12:36 PM
Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference - GlobeNewswire (press release)Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference - GlobeNewswire (press release)
globenewswire.com - March 18 at 3:56 PM
Reata Selected to Present Early-Stage Programs at the BIO Asia International ConferenceReata Selected to Present Early-Stage Programs at the BIO Asia International Conference
finance.yahoo.com - March 17 at 11:08 AM
Reata Pharmaceuticals Inc (RETA) Receives Average Rating of "Hold" from BrokeragesReata Pharmaceuticals Inc (RETA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 14 at 3:42 AM
Reata Pharmaceuticals Inc (RETA) to Post Q1 2018 Earnings of ($0.55) Per Share, Jefferies Group ForecastsReata Pharmaceuticals Inc (RETA) to Post Q1 2018 Earnings of ($0.55) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 8 at 6:30 AM
Prosight Management LP Purchases Shares of 172,897 Reata Pharmaceuticals Inc (RETA)Prosight Management LP Purchases Shares of 172,897 Reata Pharmaceuticals Inc (RETA)
www.americanbankingnews.com - March 5 at 3:30 PM
Reata Pharmaceuticals (RETA) Announces Quarterly  Earnings Results, Misses Expectations By $0.08 EPSReata Pharmaceuticals (RETA) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - March 3 at 10:38 AM

SEC Filings

Reata Pharmaceuticals (NASDAQ:RETA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Reata Pharmaceuticals (NASDAQ:RETA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Reata Pharmaceuticals (NASDAQ RETA) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.